VitalConnect secures $33M for stick-on vital sign tracker

The VitalPatch monitors eight vital signs, including heart rate and motion, and could detect changes in a patient's physiology earlier. (VitalConnect)

VitalConnect raised $33 million in series C funding, which will boost the commercialization of its disposable, adhesive biosensor for patient monitoring in hospitals or at home.

Launched in March last year, the VitalPatch is a small, wireless sensor that tracks eight vital signs: skin temperature, breathing rate, posture, motion, including falls, ECG, heart rate and variability in heart rate. The VitalConnect Platform integrates these data into a cloud-based system, where they are processed and analyzed, and may be viewed by healthcare professionals on a computer or mobile device.

The patch is powered by a disposable zinc battery, which can last up to four days.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Continuous monitoring of vital signs could help spot changes in patient physiology sooner, which could improve care for patients and reduce time spent in intensive care.

RELATED: FierceMedicalDevices’ 2016 Fierce 15 - VitalConnect

“The integration of wearable biosensors into existing and emerging healthcare environments will change the care paradigm within hospitals as well as enable virtual care opportunities that were never before possible,” said VitalConnect CEO Nersi Nazari in a statement. “Biosensors, when paired with sophisticated data analytics platforms, have the unique opportunity to enable better care for patients while reducing costs for hospitals—a win for both patients and providers.”

MVM Life Science Partners and Baxter’s venture arm led the financing. Last June, VitalConnect picked up $17.5 million in debt from Perceptive Advisors and raised $7.8 million to bring its series B total to $22.1 million.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.